Given that we have demonstrated that cuproptosis increases the expression levels of HLA-DRA, we hypothesize that promoting the expression of HLA-DRA in ccRCC patients through cuproptosis will enhance the sensitivity to immune checkpoint blockade. Here, HLA-DRA is linked to nonpapillary renal cell carcinoma.